REMS For Obesity Drugs May Need More Specifics After Qnexa Advisory Panel

Providing the details of a risk management strategy would aid sponsors in their quest for a positive response to weight-loss drugs from FDA's Endocrinologic and Metabolic Drugs Advisory Committee, the panel indicated July 15 in its review of Vivus's Qnexa

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet